|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM285773860 |
| 003 |
DE-627 |
| 005 |
20231225050159.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2019 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1021/acs.langmuir.8b00851
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0952.xml
|
| 035 |
|
|
|a (DE-627)NLM285773860
|
| 035 |
|
|
|a (NLM)29933695
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Lin, Weifeng
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Development of Zwitterionic Polypeptide Nanoformulation with High Doxorubicin Loading Content for Targeted Drug Delivery
|
| 264 |
|
1 |
|c 2019
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 15.01.2020
|
| 500 |
|
|
|a Date Revised 15.01.2020
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Much attention has been drawn to targeted nanodrug delivery systems due to their high therapeutic efficacy in cancer treatment. In this work, doxorubicin (DOX) was incorporated into a zwitterionic arginyl-glycyl-aspartic acid (RGD)-conjugated polypeptide by an emulsion solvent evaporation technique with high drug loading content (45%) and high drug loading efficiency (95%). This zwitterionic nanoformulation showed excellent colloidal stability at high dilution and in serum. The pH-induced disintegration and enzyme-induced degradation of the nanoformulation were confirmed by dynamic light scattering and gel permeation chromatography. Efficient internalization of DOX in the cells and high antitumor activity in vitro was observed. Compared with the free drug, this nanoformulation showed higher accumulation in tumor and lower systemic toxicity in vivo. The DOX-loaded zwitterionic RGD-conjugated polypeptide vesicles show potential application for targeted drug delivery in the clinic
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Antineoplastic Agents
|2 NLM
|
| 650 |
|
7 |
|a Drug Carriers
|2 NLM
|
| 650 |
|
7 |
|a Peptides, Cyclic
|2 NLM
|
| 650 |
|
7 |
|a Polylysine
|2 NLM
|
| 650 |
|
7 |
|a 25104-18-1
|2 NLM
|
| 650 |
|
7 |
|a Polyglutamic Acid
|2 NLM
|
| 650 |
|
7 |
|a 25513-46-6
|2 NLM
|
| 650 |
|
7 |
|a poly(glutamic acid-lysine)
|2 NLM
|
| 650 |
|
7 |
|a 27456-64-0
|2 NLM
|
| 650 |
|
7 |
|a Doxorubicin
|2 NLM
|
| 650 |
|
7 |
|a 80168379AG
|2 NLM
|
| 700 |
1 |
|
|a Ma, Guanglong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yuan, Zhefan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Qian, Haofeng
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xu, Liangbo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sidransky, Elie
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, Shengfu
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Langmuir : the ACS journal of surfaces and colloids
|d 1992
|g 35(2019), 5 vom: 05. Feb., Seite 1273-1283
|w (DE-627)NLM098181009
|x 1520-5827
|7 nnns
|
| 773 |
1 |
8 |
|g volume:35
|g year:2019
|g number:5
|g day:05
|g month:02
|g pages:1273-1283
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1021/acs.langmuir.8b00851
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_721
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 35
|j 2019
|e 5
|b 05
|c 02
|h 1273-1283
|